Conavi Medical Plans for Strategic Expansion in U.S. Market

Conavi Medical Inc., a leader of hybrid imaging guidance for common minimally invasive heart procedures, plans to expand the presence of its Novasight Hybrid System in the U.S. market in 2022 under the guidance of its new leadership team.

Thomas Looby, chief executive officer, Conavi Medical, appointed in April of 2021 to focus on the company’s strategic growth plans, has set the U.S. market as the company’s near-term focus. Looby’s extensive background in leading medical device companies and developing global markets for cutting-edge technology bolsters the leadership team as they prepare for new milestones. To efficiently execute this expansion, Robert Skidmore joined as vice president of Operations in October 2021 to scale up production to meet the expected demand.

“The Conavi team is aligned on a cohesive plan to introduce and drive the value proposition of our innovative system to select early adopters and luminaries in the U.S.,” said Looby. “Our recently raised capital leaves us well positioned for operational growth. We are already ramping up manufacturing and expanding our U.S. based clinical team to support our customers.” 

The Novasight Hybrid System is a new imaging platform for use by interventional cardiologists during common minimally invasive heart procedures. This patented technology is the first and only clinical system that enables simultaneous and co-registered imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT).

Dr. Brian Courtney, chief medical officer and co-founder, Conavi Medical, said, “The clinical practice guidelines for intravascular imaging were recently updated to reflect clinical data on how intravascular imaging can improve clinical outcomes for angioplasty procedures. This is an important step in increasing the use of advanced imaging in North America.” He added, “We believe hybrid imaging with IVUS and OCT will have an important role in clinical, research and educational applications.”

Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration, and regulatory approval for clinical use from Health Canada, and the Ministry of Health, Labor and Welfare (MHLW) in Japan.

For more information: http://conavi.com/